52 related articles for article (PubMed ID: 36297469)
1. Molecular docking analysis of sphingosine kinase 1 inhibitors for cancer management.
Barnawi J
Bioinformation; 2023; 19(5):571-576. PubMed ID: 37886152
[TBL] [Abstract][Full Text] [Related]
2. Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis.
Liu XT; Huang Y; Liu D; Jiang YC; Zhao M; Chung LH; Han XD; Zhao Y; Chen J; Coleman P; Ting KK; Tran C; Su Y; Dennis CV; Bhatnagar A; Liu K; Don AS; Vadas MA; Gorrell MD; Zhang S; Murray M; Kavurma MM; McCaughan GW; Gamble JR; Qi Y
J Transl Med; 2024 Jan; 22(1):43. PubMed ID: 38200582
[TBL] [Abstract][Full Text] [Related]
3. Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.
Pyne NJ; McNaughton M; Boomkamp S; MacRitchie N; Evangelisti C; Martelli AM; Jiang HR; Ubhi S; Pyne S
Adv Biol Regul; 2016 Jan; 60():151-159. PubMed ID: 26429117
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases.
Adams DR; Pyne S; Pyne NJ
Cell Signal; 2020 Dec; 76():109806. PubMed ID: 33035646
[TBL] [Abstract][Full Text] [Related]
5. Novel Dimer Derivatives of PF-543 as Potential Antitumor Agents for the Treatment of Non-Small Cell Lung Cancer.
Kim SB; Limbu KR; Oh YS; Kim SL; Park SK; Baek DJ; Park EY
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297469
[TBL] [Abstract][Full Text] [Related]
6. Determining the Anticancer Activity of Sphingosine Kinase Inhibitors Containing Heteroatoms in Their Tail Structure.
Shrestha J; Kim SW; Kim SB; Oh YS; Ki SH; Lee T; Kim SB; Park T; Baek DJ; Park EY
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057052
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Evaluation of BODIPY-PF-543.
Shrestha J; Hwang GT; Lee T; Kim SW; Oh YS; Kwon Y; Hong SW; Kim S; Seop Moon H; Baek DJ; Park EY
Molecules; 2019 Dec; 24(23):. PubMed ID: 31810327
[TBL] [Abstract][Full Text] [Related]
8. SK1 Inhibitor RB005 Induces Apoptosis in Colorectal Cancer Cells through SK1 Inhibition Dependent and Independent Pathway.
Shrestha J; Shamshiddinova M; Lee YM; Oh YS; Baek DJ; Park EY
Curr Mol Pharmacol; 2022; 15(3):570-581. PubMed ID: 34382511
[TBL] [Abstract][Full Text] [Related]
9. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases.
Gao P; Peterson YK; Smith RA; Smith CD
PLoS One; 2012; 7(9):e44543. PubMed ID: 22970244
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of PP2A-Activating PF-543 Derivatives and Investigation of Their Inhibitory Effects on Pancreatic Cancer Cells.
Kim SB; Oh YS; Kim KJ; Cho SW; Park SK; Baek DJ; Park EY
Molecules; 2022 May; 27(10):. PubMed ID: 35630821
[TBL] [Abstract][Full Text] [Related]
11. Design and Development of Novel Urea, Sulfonyltriurea, and Sulfonamide Derivatives as Potential Inhibitors of
Roy S; Mahapatra AD; Mohammad T; Gupta P; Alajmi MF; Hussain A; Rehman MT; Datta B; Hassan MI
Pharmaceuticals (Basel); 2020 Jun; 13(6):. PubMed ID: 32526899
[TBL] [Abstract][Full Text] [Related]
12. Verification of the Necessity of the Tolyl Group of PF-543 for Sphingosine Kinase 1 Inhibitory Activity.
Kim SB; Lee T; Moon HS; Ki SH; Oh YS; Lee JY; Kim SB; Park JE; Kwon Y; Kim S; Baek DJ; Park EY
Molecules; 2020 May; 25(11):. PubMed ID: 32471162
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine.
Gachechiladze M; Tichý T; Kolek V; Grygárková I; Klein J; Mgebrishvili G; Kharaishvili G; Janíková M; Smičková P; Cierna L; Pitson S; Maddelein ML; Cuvillier O; Škarda J
Oncol Lett; 2019 Aug; 18(2):1259-1266. PubMed ID: 31423186
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cetuximab and
Miyake N; Chikumi H; Yamaguchi K; Takata M; Takata M; Okada K; Kitaura T; Nakamoto M; Yamasaki A
Yonago Acta Med; 2019 Mar; 62(1):85-93. PubMed ID: 30962749
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
